Cargando…
The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed pr...
Autores principales: | Tang, Hiu, Kulkarni, Sanat, Peters, Christina, Eddison, Jasper, Al-Ani, Maryam, Madhusudan, Srinivasan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138422/ https://www.ncbi.nlm.nih.gov/pubmed/37108451 http://dx.doi.org/10.3390/ijms24087293 |
Ejemplares similares
-
Towards Personalized Management of Ovarian Cancer
por: Algethami, Mashael, et al.
Publicado: (2022) -
Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022) -
Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review
por: Shah, Hina J., et al.
Publicado: (2023) -
Polypharmacology in Precision Oncology: Current Applications and Future
Prospects
por: Antolin, Albert A., et al.
Publicado: (2016) -
A step towards the ambition of precision oncology in recurrent ovarian cancer
por: Wijaya, Silvana Talisa, et al.
Publicado: (2022)